{"id":17165,"date":"2013-10-16T10:30:00","date_gmt":"2013-10-16T08:30:00","guid":{"rendered":"http:\/\/www.fedaiisf.it\/generici-7-su-10-dicono-si-ma-italia-ancora-indietro\/"},"modified":"2013-10-16T10:30:00","modified_gmt":"2013-10-16T08:30:00","slug":"generici-7-su-10-dicono-si-ma-italia-ancora-indietro","status":"publish","type":"post","link":"https:\/\/www.fedaiisf.it\/en\/generici-7-su-10-dicono-si-ma-italia-ancora-indietro\/","title":{"rendered":"Generics, 7 out of 10 say yes but Italy is still behind"},"content":{"rendered":"<p class=\"MsoNormal\" style=\"text-align: left; margin: 0cm 0cm 0pt\"><span style=\"font-size: 14pt\"><font face=\"Times New Roman\">(ANSA) - ROME, FEBRUARY 14 - The Antitrust has launched an investigation into the pharmaceutical companies Roche and Novartis to verify whether they have implemented &#039;restrictive competition behavior&#039; in the sale of drugs for the treatment of ophthalmic diseases. According to some reports, the two groups agreed to exclude the use in Italy of the drug Avastin, sold by Roche, for the treatment of certain eye diseases common among the elderly, for the benefit of Lucentis of Novartis.<\/font><\/span><\/p>\n<p class=\"MsoNormal\" style=\"text-align: left; margin: 0cm 0cm 0pt\"><span style=\"font-size: 14pt\"><font face=\"Times New Roman\"><\/p>\n<p><span style=\"font-family: &quot;Arial&quot;,&quot;sans-serif&quot;; color: black; font-size: 1pt; mso-fareast-font-family: 'Times New Roman'; mso-fareast-language: IT; mso-ansi-language: IT; mso-bidi-language: AR-SA\"><a href=\"http:\/\/aboutpharma.mailmta.com\/nl\/l.jsp?02.7j.ZCZ.Jf.By.p4wX\" target=\"_blank\" rel=\"noopener\"><b><span style=\"color: #d9000b; font-size: 8.5pt\">Download pdf \u00bb<\/span><\/b><\/a><\/span><\/p>\n<p><\/font><\/span><\/p>","protected":false},"excerpt":{"rendered":"<p>(ANSA) &#8211; ROMA, 14 FEB &#8211; L&#8217;Antitrust ha avviato un&#8217;istruttoria nei confronti delle aziende farmaceutiche Roche e Novartis per verificare se abbiano messo in atto &#8216;comportamenti restrittivi della concorrenza&#8217; nella vendita di farmaci per la cura di patologie oftalmiche. Secondo alcune denunce i due gruppi si sarebbero accordati per escludere l&#8217;utilizzazione in Italia, per la &hellip;<\/p>","protected":false},"author":1,"featured_media":9846,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[90],"tags":[],"class_list":["post-17165","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-fedaiisf-archivio-storico"],"amp_enabled":true,"_links":{"self":[{"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/posts\/17165","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/comments?post=17165"}],"version-history":[{"count":0,"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/posts\/17165\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/media\/9846"}],"wp:attachment":[{"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/media?parent=17165"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/categories?post=17165"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/tags?post=17165"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}